Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, and surgical resection is a requirement for a potential cure. However, the majority of patients are diagnosed with advanced-stage disease, either metastatic (50%) or locally advanced cancer (30%). Although palliative chemotherapy is the standard of care for patients with metastatic disease, management of locally advanced adenocarcinoma is controversial. Several treatment options, including extended surgical resections, neoadjuvant therapy with subsequent resections, as well as palliative radiotherapy and/or chemotherapy, should be considered. However, there is little evidence available to support treatment options for locally advanced disease. As valid predictive biomarkers for stratification of therapy are not available today, future trials need to define the role of the different treatment options. This Review summarizes the current evidence and discusses available treatment options for both locally advanced and metastatic pancreatic adenocarcinoma.
Surgical resection of pancreatic cancer is a requirement for potential cure; the 5-year-survival after resection plus adjuvant chemotherapy is over 20%
Locally advanced primarily irresectable pancreatic carcinomas should be treated with neoadjuvant treatment (chemoradiotherapy in most cases) to down-stage or even down-size the tumour to obtain the chance of secondary resection
Borderline resectable pancreatic cancers can be treated by extended surgery and adjuvant chemotherapy; neoadjuvant treatment regimens to achieve better tumour control before surgery are an alternative in these patients
The FOLFIRINOX protocol and nab-paclitaxel are new therapy options that improve survival for patients with metastatic disease and a good performance status
Recent advances in understanding the molecular pathogenesis of the disease raise the hope that a more-personalized therapy will be possible in the near future
Centralization of the treatment of pancreatic cancer in high-volume hospitals reduces perioperative morbidity and mortality, and improves long-term oncological outcome
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10–29 (2012).
Bilimoria, K. Y. et al. National failure to operate on early stage pancreatic cancer. Ann. Surg. 246, 173–180 (2007).
Hartwig, W. et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann. Surg. 254, 311–319 (2011).
Mayo, S. C. et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 118, 2674–2681 (2012).
Neoptolemos, J. P. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200–1210 (2004).
Oettle, H. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297, 267–277 (2007).
Zhou, Y., Zhang, Z., Liu, Y., Li, B. & Xu, D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J. Surg. 36, 884–891 (2012).
Hartwig, W. et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann. Surg. 250, 81–87 (2009).
Gillen, S., Schuster, T., Meyer Zum Buschenfelde, C., Friess, H. & Kleeff, J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 7, e1000267 (2010).
Varadhachary, G. R. et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann. Surg. Oncol. 13, 1035–1046 (2006).
Callery, M. P. et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann. Surg. Oncol. 16, 1727–1733 (2009).
Hoffman, J. P. et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am. J. Surg. 169, 71–77 (1995).
Bilimoria, K. Y. et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer 110, 1227–1234 (2007).
Imamura, M. et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 136, 1003–1011 (2004).
Adler, G. et al. Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies [German]. Dtsch Med. Wochenschr. 132, 1696–1700 (2007).
Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J. Natl Compr. Canc. Netw. 10, 703–713 (2012).
Kulu, Y. et al. Total pancreatectomy for pancreatic cancer: indications and operative technique. HPB (Oxford) 11, 469–475 (2009).
Reddy, S. et al. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Ann. Surg. 250, 282–287 (2009).
Burdelski, C. M. et al. Multivisceral resections in pancreatic cancer: identification of risk factors. World J. Surg. 35, 2756–2763 (2011).
Chua, T. C. & Saxena, A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J. Gastrointest. Surg. 14, 1442–1452 (2010).
Mollberg, N. et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann. Surg. 254, 882–893 (2011).
Müller, S. A. et al. Vascular resection in pancreatic cancer surgery: survival determinants. J. Gastrointest. Surg. 13, 784–792 (2009).
Evans, D. B., Erickson, B. A. & Ritch, P. Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. Ann. Surg. Oncol. 17, 2803–2805 (2010).
Butturini, G. et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch. Surg. 143, 75–83 (2008).
Verbeke, C. S. et al. Redefining the R1 resection in pancreatic cancer. Br. J. Surg. 93, 1232–1237 (2006).
Esposito, I. et al. Most pancreatic cancer resections are R1 resections. Ann. Surg. Oncol. 15, 1651–1660 (2008).
Royal College of Pathologists. Dataset for the histopathologic reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct [online], (2010).
Konstantinidis, I. T. et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann. Surg. 257, 731–736 (2013).
Weitz, J., Rahbari, N., Koch, M. & Büchler, M. W. The “artery first” approach for resection of pancreatic head cancer. J. Am. Coll. Surg. 210, e1–e4 (2010).
Pessaux, P. et al. Preliminary experience with the hanging maneuver for pancreaticoduodenectomy. Eur. J. Surg. Oncol. 35, 1006–1010 (2009).
Hackert, T., Werner, J., Weitz, J., Schmidt, J. & Büchler, M. W. Uncinate process first--a novel approach for pancreatic head resection. Langenbecks Arch. Surg. 395, 1161–1164 (2010).
Mitchem, J. B. et al. Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure. J. Am. Coll. Surg. 214, 46–52 (2012).
Kurosaki, I., Minagawa, M., Takano, K., Takizawa, K. & Hatakeyama, K. Left posterior approach to the superior mesenteric vascular pedicle in pancreaticoduodenectomy for cancer of the pancreatic head. JOP 12, 220–229 (2011).
Birkmeyer, J. D. et al. Hospital volume and surgical mortality in the United States. N. Engl. J. Med. 346, 1128–1137 (2002).
Birkmeyer, J. D., Sun, Y., Wong, S. L. & Stukel, T. A. Hospital volume and late survival after cancer surgery. Ann. Surg. 245, 777–783 (2007).
Gooiker, G. A. et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br. J. Surg. 98, 485–494 (2011).
Chen, J. W. et al. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford) 12, 101–108 (2010).
Wasif, N. et al. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann. Surg. Oncol. 17, 2312–2320 (2010).
van Roest, M. H. et al. Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization. Ann. Surg. 248, 97–103 (2008).
Humphris, J. L. et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann. Oncol. 23, 1713–1722 (2012).
Hartwig, W. et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann. Surg. Oncol. http://dx.doi.org/10.1245/s10434-012-2809-1.
Klauss, M. et al. Multidetector CT evaluation of the course of nonresectable pancreatic carcinomas with neoadjuvant therapy. Pancreatology 9, 621–630 (2009).
Klauss, M. et al. Computed tomography perfusion analysis of pancreatic carcinoma. J. Comput. Assist. Tomogr. 36, 237–242 (2012).
Morgan, D. E. et al. Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT. AJR Am. J. Roentgenol. 194, 615–622 (2010).
Andriulli, A. et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann. Surg. Oncol. 19, 1644–1662 (2012).
Habermehl, D. et al. Neoadjuvant chemoradiation with gemcitabine for locally advanced pancreatic cancer. Radiat. Oncol. 7, 28 (2012).
Strobel, O. et al. Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery 152, S33–S42 (2012).
Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073–1081 (2010).
Ueno, H. et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br. J. Cancer 101, 908–915 (2009).
Schmidt, J. et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J. Clin. Oncol. 30, 4077–4083 (2012).
Chauffert, B. et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–2001 FFCD/SFRO study. Ann. Oncol. 19, 1592–1599 (2008).
Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 362, 1605–1617 (2010).
Lillemoe, K. D. et al. Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann. Surg. 223, 718–725 (1996).
Reinders, M. E. et al. Outcome of microscopically nonradical, subtotal pancreaticoduodenectomy (Whipple's resection) for treatment of pancreatic head tumors. World J. Surg. 19, 410–414 (1995).
Gillen, S., Schuster, T., Friess, H. & Kleeff, J. Palliative resections versus palliative bypass procedures in pancreatic cancer--a systematic review. Am. J. Surg. 203, 496–502 (2012).
Schniewind, B. et al. Bypass surgery versus palliative pancreaticoduodenectomy in patients with advanced ductal adenocarcinoma of the pancreatic head, with an emphasis on quality of life analyses. Ann. Surg. Oncol. 13, 1403–1411 (2006).
Köninger, J. et al. R2 resection in pancreatic cancer--does it make sense? Langenbecks Arch. Surg. 393, 929–934 (2008).
Bockhorn, M. et al. Crossing the Rubicon: when pancreatic resection with curative intent ends in an R2 status. Impact of “desmoplastic pseudo-pancreatitis” and anatomical site of irresectability. Ann. Surg. Oncol. 16, 1212–1221 (2009).
Tachezy, M. et al. Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil? J. Gastrointest. Surg. 15, 829–835 (2011).
Crippa, S. et al. Quality of life in pancreatic cancer: analysis by stage and treatment. J. Gastrointest. Surg. 12, 783–793 (2008).
van Heek, N. T., van Geenen, R. C., Busch, O. R. & Gouma, D. J. Palliative treatment in “peri”-pancreatic carcinoma: stenting or surgical therapy? Acta Gastroenterol. Belg. 65, 171–175 (2002).
Taylor, M. C., McLeod, R. S. & Langer, B. Biliary stenting versus bypass surgery for the palliation of malignant distal bile duct obstruction: a meta-analysis. Liver Transpl. 6, 302–308 (2000).
Nieveen van Dijkum, E. J. et al. Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br. J. Surg. 92, 471–477 (2005).
Sohn, T. A. et al. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J. Am. Coll. Surg. 188, 658–666 (1999).
Jeurnink, S. M. et al. Predictors of survival in patients with malignant gastric outlet obstruction: a patient-oriented decision approach for palliative treatment. Dig. Liver Dis. 43, 548–552 (2011).
Baron, T. H. Surgical versus endoscopic palliation of malignant gastric outlet obstruction: big incision, little incision, or no incision? Gastroenterology 127, 1268–1269 (2004).
Tempero, M. A. et al. Pancreatic adenocarcinoma. J. Natl Compr. Canc. Netw. 8, 972–1017 (2010).
Klaassen, D. J., MacIntyre, J. M., Catton, G. E., Engstrom, P. F. & Moertel, C. G. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 3, 373–378 (1985).
Scorsetti, M. et al. Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: feasibility and clinical preliminary results. Acta Oncol. 50, 528–538 (2011).
Didolkar, M. S. et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J. Gastrointest. Surg. 14, 1547–1559 (2010).
Evans, D. B. et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 26, 3496–3502 (2008).
Whittington, R., Neuberg, D., Tester, W. J., Benson, A. B. 3rd & Haller, D. G. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. 13, 227–232 (1995).
Breslin, T. M. et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann. Surg. Oncol. 8, 123–132 (2001).
Combs, S. E., Habermehl, D., Werner, J., Büchler, M. W. & Debus, J. Strategies for preoperative downsizing in patients with local nonresectable pancreatic cancer [German]. Chirurg 82, 981–988 (2011).
Morganti, A. G. et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann. Surg. Oncol. 17, 194–205 (2010).
Moertel, C. G. et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48, 1705–1710 (1981).
Varadhachary, G. R. et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 26, 3487–3495 (2008).
Kastl, S. et al. Neoadjuvant radio-chemotherapy in advanced primarily non-resectable carcinomas of the pancreas. Eur. J. Surg. Oncol. 26, 578–582 (2000).
Murphy, J. D. et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, 801–808 (2007).
Girard, N. et al. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 phase I trial. Int. J. Radiat. Oncol. Biol. Phys. 77, 1426–1432 (2010).
Shibuya, K. et al. Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am. J. Clin. Oncol. 34, 115–119 (2011).
Crane, C. H. et al. Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin. Oncol. 28, 25–33 (2001).
Haddock, M. G. et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J. Clin. Oncol. 25, 2567–2572 (2007).
Jia, Y., Wang, T. J., Allendorf, J. & Saif, M. W. Management of borderline resectable pancreatic adenocarcinoma. JOP 13, 147–150 (2012).
Quiros, R. M., Brown, K. M. & Hoffman, J. P. Neoadjuvant therapy in pancreatic cancer. Cancer Invest. 25, 267–273 (2007).
White, R. R. et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann. Surg. Oncol. 8, 758–765 (2001).
Evans, D. B. et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch. Surg. 127, 1335–1339 (1992).
Massucco, P. et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann. Surg. Oncol. 13, 1201–1208 (2006).
Ammori, J. B. et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J. Gastrointest. Surg. 7, 766–772 (2003).
Pingpank, J. F. et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J. Gastrointest. Surg. 5, 121–130 (2001).
Huguet, F., Goodman, K. A., Azria, D., Racadot, S. & Abrams, R. A. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Int. J. Radiat. Oncol. Biol. Phys. 83, 1355–1364 (2012).
Lominska, C. E., Unger, K., Nasr, N. M., Haddad, N. & Gagnon, G. Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas. Radiat. Oncol. 7, 74 (2012).
Goyal, K. et al. Stereotactic body radiation therapy for nonresectable tumors of the pancreas. J. Surg. Res. 174, 319–325 (2012).
Mahadevan, A. et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int. J. Radiat. Oncol. Biol. Phys. 81, e615–e622 (2011).
Schellenberg, D. et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 81, 181–188 (2011).
Rwigema, J. C. et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am. J. Clin. Oncol. 34, 63–69 (2011).
Krempien, R. et al. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283]. BMC Cancer 5, 131 (2005).
Abelson, J. A. et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 15, 82 (2012).
Suit, H. et al. Proton beams to replace photon beams in radical dose treatments. Acta Oncol. 42, 800–808 (2003).
Combs, S. E., Jäkel, O., Haberer, T. & Debus, J. Particle therapy at the Heidelberg Ion Therapy Center (HIT)—integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany. Radiother. Oncol. 95, 41–44 (2010).
Schulz-Ertner, D. & Tsujii, H. Particle radiation therapy using proton and heavier ion beams. J. Clin. Oncol. 25, 953–964 (2007).
Shinoto, M. et al. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 119, 45–51 (2013).
Okada, T. et al. Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). J. Radiat. Res. 51, 355–364 (2010).
Oonishi, K. et al. Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother. Oncol. 105, 258–265 (2012).
ElShafie, R. et al. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. J. Rad. Res. (in press).
Yamada, S. et al. Carbon ion radiotherapy for patients with gastrointestinal cancer. Particle Therapy Co-Operative Group meeting 49, Chiba, Japan (2010).
US National Library of Medicine. ClinicalTrials.gov [online], (2013).
Palmer, D. H. et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann. Surg. Oncol. 14, 2088–2096 (2007).
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
Hosein, P. J. et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 12, 199 (2012).
Mondo, E. L., Noel, M. S., Katz, A. W., Schoeniger, L. O. & Hezel, A. F. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability. J. Clin. Oncol. 31, e37–e39 (2013).
Vincent, A., Herman, J., Schulick, R., Hruban, R. H. & Goggins, M. Pancreatic cancer. Lancet 378, 607–620 (2011).
Burris, H. A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403–2413 (1997).
Heinemann, V., Haas, M. & Boeck, S. Systemic treatment of advanced pancreatic cancer. Cancer Treat. Rev. 38, 843–853 (2012).
Warsame, R. & Grothey, A. Treatment options for advanced pancreatic cancer: a review. Expert Rev. Anticancer Ther. 12, 1327–1336 (2012).
Zafar, S. F. & El-Rayes, B. F. Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma. Am. J. Clin. Oncol. http://dx.doi.org/10.1097/COC.0b013e318248d8bb.
Heinemann, V., Boeck, S., Hinke, A., Labianca, R. & Louvet, C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8, 82 (2008).
Cunningham, D. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27, 5513–5518 (2009).
Gourgou-Bourgade, S. et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. 31, 23–29 (2013).
Gradishar, W. J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother. 7, 1041–1053 (2006).
Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548–4554 (2011).
Feig, C. et al. The pancreas cancer microenvironment. Clin. Cancer Res. 18, 4266–4276 (2012).
Neesse, A. et al. Stromal biology and therapy in pancreatic cancer. Gut 60, 861–868 (2011).
Pelzer, U. et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur. J. Cancer 47, 1676–1681 (2011).
Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28–39 (2009).
Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960–1966 (2007).
Miksad, R. A., Schnipper, L. & Goldstein, M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J. Clin. Oncol. 25, 4506–4507 (2007).
Stepanski, E. J. et al. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas 42, 32–36 (2013).
Heinemann, V. et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut http://dx.doi.org/10.1136/gutjnl-2012-302759.
Aranda, E. et al. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann. Oncol. 23, 1919–1925 (2012).
Philip, P. A. et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol. 28, 3605–3610 (2010).
Van Cutsem, E. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231–2237 (2009).
Kindler, H. L. et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 12, 256–262 (2011).
Van Cutsem, E. et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22, 1430–1438 (2004).
Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008).
Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).
Iacobuzio-Donahue, C. A., Velculescu, V. E., Wolfgang, C. L. & Hruban, R. H. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin. Cancer Res. 18, 4257–4265 (2012).
Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
Yachida, S. et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin. Cancer Res. 18, 6339–6347 (2012).
Martini, M., Vecchione, L., Siena, S., Tejpar, S. & Bardelli, A. Targeted therapies: how personal should we go? Nat. Rev. Clin. Oncol. 9, 87–97 (2012).
Marechal, R. et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143, 664–674 (2012).
Crane, C. H. Is personalization of care coming to pancreatic oncology? Ann. Surg. Oncol. 20, 355–356 (2013).
Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500–503 (2011).
Cui, Y. et al. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin. Cancer Res. 18, 6519–6530 (2012).
Villarroel, M. C. et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther. 10, 3–8 (2011).
Jones, S. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).
Hidalgo, M. & Von Hoff, D. D. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin. Cancer Res. 18, 4249–4256 (2012).
Tholey, R., Sawicki, J. A. & Brody, J. R. Molecular-based and alternative therapies for pancreatic cancer: looking “out of the box”. Cancer J. 18, 665–673 (2012).
Cinar, P. & Tempero, M. A. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 18, 653–664 (2012).
Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612–1616 (2011).
Soares, K. C., Zheng, L., Edil, B. & Jaffee, E. M. Vaccines for pancreatic cancer. Cancer J. 18, 642–652 (2012).
Wennier, S., Li, S. & McFadden, G. Oncolytic virotherapy for pancreatic cancer. Expert Rev. Mol. Med. 13, e18 (2011).
Von Hoff, D. D. et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT) [abstract]. J. Clin. Oncol. 30 (Suppl. 34), LBA148 (2012).
C. Springfeld has received honoraria for serving on an advisory board of Celgene. The other authors declare no competing interests.
About this article
Cite this article
Werner, J., Combs, S., Springfeld, C. et al. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol 10, 323–333 (2013). https://doi.org/10.1038/nrclinonc.2013.66
The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy
Journal of Gastroenterology (2021)
Cellular and Molecular Gastroenterology and Hepatology (2021)
pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer
ACS Applied Materials & Interfaces (2021)
BMC Surgery (2021)
Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
International Journal of Molecular Sciences (2021)